SCOPUS 정보 검색 플랫폼

Blood

Volumn 114, Issue 5, 2009, Pages 931-932

Bortezomib paradigm shift in myeloma

(1) McConkey, David J a

a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RELAPSE; CELL SURVIVAL; CLINICAL TRIAL; GENE MUTATION; HUMAN; MULTIPLE MYELOMA; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 70449480557 PISSN: 00064971 EISSN: 15280020 Source Type: Journal
DOI: 10.1182/blood-2009-06-223230 Document Type: Note

Times cited : (14)

References (10)

1
- 2342667387
- The development of proteasome inhibitors as anticancer drugs
- DOI 10.1016/S1535-6108(04)00120-5, PII S1535610804001205
- Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell. 2004;5:417-421. (Pubitemid 38610244)
- (2004) Cancer Cell , vol.5 , Issue.5 , pp. 417-421
- Adams, J.¹

2
- 0037973279
- A phase 2 study of Bortezomib in relapsed, refractory myeloma
- DOI 10.1056/NEJMoa030288
- Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-2617. (Pubitemid 36741588)
- (2003) New England Journal of Medicine , vol.348 , Issue.26 , pp. 2609-2617
- Richardson, P.G.¹ Barlogie, B.² Berenson, J.³ Singhal, S.⁴ Jagannath, S.⁵ Irwin, D.⁶ Rajkumar, S.V.⁷ Srkalovic, G.⁸ Alsina, M.⁹ Alexanian, R.¹⁰ Siegel, D.¹¹ Orlowski, R.Z.¹² Kuter, D.¹³ Limentani, S.A.¹⁴ Lee, S.¹⁵ Hideshima, T.¹⁶ Esseltine, D.-L.¹⁷ Kauffman, M.¹⁸ Adams, J.¹⁹ Schenkein, D.P.²⁰ Anderson, K.C.²¹ more..

3
- 0036020941
- NF-kappaB as a therapeutic target in cancer
- Orlowski RZ, Baldwin AS Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002;8:385-389.
- (2002) Trends Mol Med , vol.8 , pp. 385-389
- Orlowski, R.Z.¹ Baldwin Jr., A.S.²

4
- 0033177897
- NF-kappa B and chemoresistance: Potentiation of cancer drugs via inhibition of NF-kappa B
- Cusack JC, Liu R, Baldwin AS. NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist Updat. 1999;2:271-273.
- (1999) Drug Resist Updat , vol.2 , pp. 271-273
- Cusack, J.C.¹ Liu, R.² Baldwin, A.S.³

5
- 34547660308
- Promiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
- DOI 10.1016/j.ccr.2007.07.003, PII S1535610807002024
- Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007;12:131-144. (Pubitemid 47208626)
- (2007) Cancer Cell , vol.12 , Issue.2 , pp. 131-144
- Keats, J.J.¹ Fonseca, R.² Chesi, M.³ Schop, R.⁴ Baker, A.⁵ Chng, W.-J.⁶ Van Wier, S.⁷ Tiedemann, R.⁸ Shi, C.-X.⁹ Sebag, M.¹⁰ Braggio, E.¹¹ Henry, T.¹² Zhu, Y.-X.¹³ Fogle, H.¹⁴ Price-Troska, T.¹⁵ Ahmann, G.¹⁶ Mancini, C.¹⁷ Brents, L.A.¹⁸ Kumar, S.¹⁹ Greipp, P.²⁰ more..

6
- 18544367201
- NF-κB as a therapeutic target in multiple myeloma
- DOI 10.1074/jbc.M200360200
- Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-16647. (Pubitemid 34967682)
- (2002) Journal of Biological Chemistry , vol.277 , Issue.19 , pp. 16639-16647
- Hideshima, T.¹ Chauhan, D.² Richardson, P.³ Mitsiades, C.⁴ Mitsiades, N.⁵ Hayashi, T.⁶ Munshi, N.⁷ Dang, L.⁸ Castro, A.⁹ Palombella, V.¹⁰ Adams, J.¹¹ Anderson, K.C.¹²

7
- 70349243697
- Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells
- Hideshima T, Ikeda H, Chauhan D, et al. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood. 2009;114:1046-1052.
- (2009) Blood , vol.114 , pp. 1046-1052
- Hideshima, T.¹ Ikeda, H.² Chauhan, D.³

8
- 20844435806
- Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma
- DOI 10.1073/pnas.0503221102
- Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005;102:8567-8572. (Pubitemid 40862776)
- (2005) Proceedings of the National Academy of Sciences of the United States of America , vol.102 , Issue.24 , pp. 8567-8572
- Hideshima, T.¹ Bradner, J.E.² Wong, J.³ Chauhan, D.⁴ Richardson, P.⁵ Schreiber, S.L.⁶ Anderson, K.C.⁷

9
- 53049110009
- Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA
- Nawrocki ST, Carew JS, Maclean KH, et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood. 2008;112:2917-2926.
- (2008) Blood , vol.112 , pp. 2917-2926
- Nawrocki, S.T.¹ Carew, J.S.² Maclean, K.H.³

10
- 34547807613
- Global changes to the ubiquitin system in Huntington's disease
- DOI 10.1038/nature06022, PII NATURE06022
- Bennett EJ, Shaler TA, Woodman B, et al. Global changes to the ubiquitin system in Huntington's disease. Nature. 2007;448:704-708. (Pubitemid 47236860)
- (2007) Nature , vol.448 , Issue.7154 , pp. 704-708
- Bennett, E.J.¹ Shaler, T.A.² Woodman, B.³ Ryu, K.-Y.⁴ Zaitseva, T.S.⁵ Becker, C.H.⁶ Bates, G.P.⁷ Schulman, H.⁸ Kopito, R.R.⁹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.